Wednesday, April 3, 2024

Elisey Mysin

Being born with a natural talent for anything is a gift, but when you become a master of the piano before your tenth birthday, it’s a miracle. This miracle’s name is Elisey Mysin, and he’s from Russia. He’s incredibly cute with blond hair and an angelic smile, and at first glance, he’s like any 
other boy his age. When he starts to play, jaws drop.

Elisey was born in the city of Stavropol, in southwest Russia. According to his family, Elisey loved the piano before he was even born. His older sister played the piano, and whenever she practised, their mother could feel Elisey start to move and react to the music. It was almost like he was dancing!

It’s no wonder that Elisey started to learn to play the piano when he was just three. It became apparent very quickly that Elisey went beyond gifted and into prodigy levels of skill. His teachers began to compare him to the ability Mozart himself had exhibited at the same age. That’s quite a compliment! Elisey more than lives up to it.

He appeared on Russian television when he was only five, accompanying fellow Russian pianist Denis Matsuev. They played a song called Blue Bird, and the viewers were blown away by his talent.

Since then, Elisey has continued to study and currently attends the Central Music School at the Moscow State Conservatory. He is a student of Natalia Trull, an award-winning Russian pianist. He is now only twelve but has still had a career that pianists two or three times his age would envy.

He has performed many more times with fellow piano virtuoso Denis Matsuev. Elisey has also played with Russia’s National Symphony and Youth Symphony orchestras, played Chopin’s Nocturne in C♯ minor on television and at the seventeenth International Piano Forum.

The maturity and expressiveness Elisey displays is unbelieveable for such a young boy. It seems that if you’re a prodigy the usual rules do not apply. If you want to see and hear it for yourself, check out this video recorded at the Moscow Conservatory.(https://www.youtube.com/watch?v=mj2Tr-IUPhc) He plays Mozart’s concert No. 3 in D major and his perfomance is perfect, even though he can barely reach the pedals. One commenter explains this remarkable gift perfectly:

“It’s weird and beautiful how music combines all ages, from a very young pianist like him, and even elderly people plus some people with the age of like 20 to 30. Music is the only language that does not differentiate between young and old and it solely depends on talent and knowledge.”

Since it was uploaded it has been watched 4.2 million times and received 69,000 likes. It will certainly have helped swell the subscribers to Elisey’s channel, not that he really needs it. The channel has 269,000 subscribers and several of his videos have received more than a million watches. This 
would be considered extremely successful for anyone but for a boy who isn’t even twelve it’s incredible. Surely, there must be lots more to come from this young prodigy.

If you would like to see more from this talented young pianist, you can subscribe to his YouTube channel. (https://www.youtube.com/@eliseymysin)

https://www.themusicman.uk/elisey-mysin/

See: https://www.youtube.com/watch?v=n67Rf8NsxdU

https://www.youtube.com/watch?v=KeTNrIgU2k8

https://www.youtube.com/watch?v=KeTNrIgU2k8&t=160s

Tuesday, April 2, 2024

Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly

Herbst, C., Bothe, V., Wegler, M. et al. Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly. Hum. Genet. (2024). https://doi.org/10.1007/s00439-024-02655-4

Abstract

Neurons form the basic anatomical and functional structure of the nervous system, and defects in neuronal differentiation or formation of neurites are associated with various psychiatric and neurodevelopmental disorders. Dynamic changes in the cytoskeleton are essential for this process, which is, inter alia, controlled by the dedicator of cytokinesis 4 (DOCK4) through the activation of RAC1. Here, we clinically describe 7 individuals (6 males and one female) with variants in DOCK4 and overlapping phenotype of mild to severe global developmental delay. Additional symptoms include coordination or gait abnormalities, microcephaly, nonspecific brain malformations, hypotonia and seizures. Four individuals carry missense variants (three of them detected de novo) and three individuals carry null variants (two of them maternally inherited). Molecular modeling of the heterozygous missense variants suggests that the majority of them affect the globular structure of DOCK4. In vitro functional expression studies in transfected Neuro-2A cells showed that all missense variants impaired neurite outgrowth. Furthermore, Dock4 knockout Neuro-2A cells also exhibited defects in promoting neurite outgrowth. Our results, including clinical, molecular and functional data, suggest that loss-of-function variants in DOCK4 probable cause a variable spectrum of a novel neurodevelopmental disorder with microcephaly.

Poirier-Bienvenu Syndrome

Inspired by a patient

Orsini A, Santangelo A, Bravin F, Bonuccelli A, Peroni D, Battini R, Foiadelli T, Bertini V, Valetto A, Iacomino M, Nigro V, Torella AL, Scala M, Capra V, Vari MS, Fetta A, Di Pisa V, Montanari F, Epifanio R, Bonanni P, Giorda R, Operto F, Pastorino G, Sarigecili E, Sardaroglu E, Okuyaz C, Bozdogan S, Musante L, Faletra F, Zanus C, Ferretti A, Vigevano F, Striano P, Cordelli DM. Expanding Phenotype of Poirier-Bienvenu Syndrome: New Evidence from an Italian Multicentrical Cohort of Patients. Genes (Basel). 2022 Jan 30;13(2):276. doi: 10.3390/genes13020276. PMID: 35205321; PMCID: PMC8872204.

Abstract

Background: Poirier-Bienvenu Neurodevelopmental Syndrome (POBINDS) is a rare disease linked to mutations of the CSNK2B gene, which encodes for a subunit of caseinkinase CK2 involved in neuronal growth and synaptic transmission. Its main features include early-onset epilepsy and intellectual disability. Despite the lack of cases described, it appears that POBINDS could manifest with a wide range of phenotypes, possibly related to the different mutations of CSNK2B.

Methods: Our multicentric, retrospective study recruited nine patients with POBINDS, detected using next-generation sequencing panels and whole-exome sequencing. Clinical, laboratory, and neuroimaging data were reported for each patient in order to assess the severity of phenotype, and eventually, a correlation with the type of CSNK2B mutation.

Results: We reported nine unrelated patients with heterozygous de novo mutations of the CSNK2B gene. All cases presented epilepsy, and eight patients were associated with a different degree of intellectual disability. Other features detected included endocrinological and vascular abnormalities and dysmorphisms. Genetic analysis revealed six new variants of CSNK2B that have not been reported previously.

Conclusion: Although it was not possible to assess a genotype-phenotype correlation in our patients, our research further expands the phenotype spectrum of POBINDS patients, identifying new mutations occurring in the CSNK2B gene.

Chen X, Han Y, Li X, Huang S, Yuan H, Qin Y. Case report: Two cases of Poirier-Bienvenu neurodevelopmental syndrome and review of literature. Front Pediatr. 2023 Mar 20;11:967701. doi: 10.3389/fped.2023.967701. PMID: 37020656; PMCID: PMC10067874.

Abstract

The Poirier-Bienvenu neurodevelopmental syndrome (POBINDS) is a rare disease caused by mutations in the CSNK2B gene, which is characterized by intellectual disability and early-onset epilepsy. Mosaicism has not been previously reported in CSNK2B gene. POBINDS is autosomal dominant and almost all reported cases were de novo variants. Here, we report two patients were diagnosed with POBINDS. Using Whole Exome Sequencing (WES), we detected two novel CSNK2B variants in the two unrelated individuals: c.634_635del (p.Lys212AspfsTer33) and c.142C > T (p.Gln48Ter) respectively. Both of them showed mild developmental delay with early-onset and clustered seizures. The patient with c.634_635del(p.Lys212AspfsTer33) variant was mutant mosaicism, and the proportion of alleles in peripheral blood DNA was 28%. Further, the literature of patients with a de novo mutation of the CSNK2B gene was reviewed, particularly seizure semiology and genotype-phenotype correlations.

Bonanni P, Baggio M, Duma GM, Negrin S, Danieli A, Giorda R. Developmental and epilepsy spectrum of Poirier-Bienvenu neurodevelopmental syndrome: Description of a new case study and review of the available literature. Seizure. 2021 Dec;93:133-139. doi: 10.1016/j.seizure.2021.10.019. Epub 2021 Oct 27. PMID: 34740143.

Abstract

Aim: To better characterize the clinical phenotype of Poirier-Bienvenu neurodevelopmental syndrome (OMIM ID: 618,732) due to pathogenic variants of the CSNK2B gene.

Method: We reviewed the electro-clinical and developmental data of all 14 patients with de novo mutations of the CSNK2B gene reported in the literature and describe a further individual with a novel CSNK2B pathogenic variant.

Results: Clustered generalized tonic-clonic or myoclonic seizures with onset before the age of 18 months and delayed neurodevelopment were present in more than 75% of patients. Epilepsy was pharmaco-resistant in 40%. All the individuals (27%) with normal neurological development had pharmaco-sensitive epilepsy. The severity of cognitive and motor impairments was higher in the group with pharmaco-resistant epilepsy, and a statistically significant correlation between seizure control and the severity of cognitive impairment was documented (χ2(3) = 9.44; p = .024) INTERPRETATION: Early seizure onset, clustered seizures and delayed development in both males and females were early clinical markers in most patients with CSNK2B mutations. The entity of neurodevelopmental abnormalities was related to epilepsy severity. Prospective studies are required to better assess the relationship between epilepsy and developmental outcomes in this condition.

Yang Q, Zhang Q, Yi S, Qin Z, Shen F, Ou S, Luo J, He S. De Novo CSNK2B Mutations in Five Cases of Poirier-Bienvenu Neurodevelopmental Syndrome. Front Neurol. 2022 Mar 16;13:811092. doi: 10.3389/fneur.2022.811092. PMID: 35370893; PMCID: PMC8965697.

Abstract

The Poirier-Bienvenu neurodevelopmental syndrome is an autosomal dominant disorder characterized by intellectual disability and epilepsy. The disease is caused by mutations in the CSNK2B gene, which encodes the beta subunit of casein kinase II, and it has important roles in neuron development and synaptic transmission. In this study, five Chinese patients were diagnosed with Poirier-Bienvenu neurodevelopmental syndrome caused by CSNK2B mutations by whole exome sequencing. We detected four different de novo variants of the CSNK2B gene in these five unrelated Chinese patients: two novel mutations, namely, c.100delT (p.Phe34fs*16) and c.158_159insA (p.Asp55fs*4), and two recurrent mutations, namely, c.1A>G (p.Met1?) and c.332 G >C (p.R111P). All five patients showed mild-to-profound intellectual disabilities/or learning disabilities and developmental delays, with or without seizures. Although intellectual disability/developmental delay and epilepsy are the most common manifestations of CSNK2B deficiency, the clinical phenotypes of probands are highly variable, and there is no significant correlation between genotype and phenotype. An abnormal stature may be another common manifestation of CSNK2B deficiency. Here, we report the effects of growth hormone (GH) therapy on the patients' linear height. In conclusion, Poirier-Bienvenu neurodevelopmental syndrome is a highly heterogeneous disease caused by mutations in the CSNK2B gene. The phenotype was highly variable, and no significant correlation of genotype and phenotype was found. Patients with short-stature and CSNK2B deficiency may benefit from GH therapy. The identification and characterization of these novel variants will expand the genotypic and phenotypic spectrum of Poirier-Bienvenu neurodevelopmental syndrome.

Neurocutaneous melanosis


When baby Weston was born, there wasn’t the usual oohing and aahing from the nurses. Instead, his mom, Kimi, heard only concern.

“A nurse said, ‘What is that?’ and then she took him away. I didn’t understand what was happening,” says Kimi Phelps.

Weston had hundreds of brown and pink spots, some very tiny, some larger, on his face and head and down his spine. It was congenital melanocytic nevi (CMN), a fairly common birthmark that usually doesn’t cause health problems but may be associated with a rare congenital syndrome called neurocutaneous melanosis (NCM).

“I googled it in the labor room and started sobbing. I was thinking, ‘Did I cause this? Is it my fault?’ I felt so alone because I had never met another baby with it. And I asked, why, why did this happen to my son?” Kimi says.

With NCM, the spots, called nevi, are inside the body, not just outside. In other words, melanocytes, the pigment-producing cells that are on the skin, are also in the nervous system—in the brain and the spine—where they are at risk for growing and pushing on the central nervous system or becoming cancerous. The National Organization for Rare Disorders estimates that just 50,000 people in the U.S. have NCM.

To determine if Weston had NCM, he needed an MRI imaging scan under anesthesia, something his home hospital didn’t provide for newborns. They referred Kimi and her husband, Nathan, to Stanford Medicine Children’s Health.

The first doctor the family met at Stanford Children’s was Shehla Admani, MD, board certified in Pediatric Dermatology, who has experience managing CMN and other common and rare skin disorders in children.

“When looking at moles or nevi, we look for features that make us worry about melanoma. I examined each of Weston’s nevi and used a dermatoscope to evaluate their pigment patterns,” Dr. Admani says.

“Dr. Admani told me Weston’s nevi were beautiful and had beautiful borders. Thankfully, she didn’t see any indication they were cancerous,” Kimi says.

Despite Weston’s nevi looking good, Dr. Admani still wanted an MRI, since he had larger nevi, which can be associated with abnormal findings in the brain. She sees small nevi every day, but larger ones are not as common.

“When we see high-risk nevi, we order imaging scans to check for neurocutaneous melanosis. It’s rare, and it requires multidisciplinary care, which is where Stanford Children’s shines,” Dr. Admani says.

Dr. Admani immediately connected the Monterey, California, family to Pediatric Neurology because she knows that it’s shocking for parents to hear their newborn might have a rare condition, and providing care quickly helps alleviate worry.

“By plugging Weston and his family in to the specialists he needed right away, we helped them navigate the diagnosis and learn what it might mean for them,” Dr. Admani says. “Having everyone on the same page giving a consistent message—all looking out for him—is the power of our multidisciplinary care.”

The family met with Susy Jeng, MD, board certified in Child Neurology. When the MRI took four times longer than Kimi anticipated, she suspected that Weston might have NCM. While it was excruciating to wait, she appreciated the thoroughness of his diagnosis.

“They really made sure they got an image of every single nevus,” Kimi says. “When they diagnosed NCM, it wasn’t what I wanted to hear, but Dr. Jeng and her intern were amazing. I was emotional, and they brought me back to earth.”

Good news followed the hard diagnosis: Weston didn’t have any brain abnormalities or extra fluid. “We saw areas of melanosis in the brain, but we didn’t see anything concerning. He looked great,” says Dr. Jeng.

The plan is to keep a close eye out for symptoms that the melanosis is growing or changing. Since MRIs require children to be sedated, they are done as infrequently as possible.

“Neurocutaneous melanosis is very rare, and we don’t have a framework to predict outcomes,” Dr. Jeng says. “Kimi and Nathan really understand that. They accept that we have to take it one step at a time.”

Yet coping with the unknown has been hard on the family. Along with cherishing every minute they have with their happy, beautiful baby boy, they’ve had bouts of anxiety and depression.

“It’s scary that at any moment it could become active,” Kimi says. “You think it’s your fault, but it’s not. I know it is a horrible diagnosis, but he is so cute and happy, and so loved.”

While NCM has no known cure or treatment, getting a genetic test helped Weston’s doctors consider the best interventions down the road. Dr. Admani connected the family to the Genetic Disorders of the Skin Program so they could learn more about his disease.

“We know that large congenital melanocytic nevi are due to genetic mutation in the tissue where the nevi are,” says Joyce Teng, MD, PhD, board-certified in Pediatric Dermatology with a specialty in genetic conditions. To check for the mutation, Dr. Teng performed a biopsy, taking samples of Weston’s cells from a larger nevus and sending them for molecular analysis. She consulted with Weston’s parents about the risks and benefits before the biopsy and talked with them about what the mutation could mean for him.

After the tests came back, she confirmed that Weston had the mutation, including a less common fusion of mutations.

“Many cancerous cells carry this particular gene rearrangement, so this discovery has identified a potential target for future care,” Dr. Teng says.

Since NCM can affect the eyes, Weston is being followed by a Stanford Children’s ophthalmologist. He also has received voice and swallow therapy for a swallowing issue and gastroenterology care for reflux.

“Being able to go to Stanford Children’s and see a team of specialists for everything Weston needs is wonderful. It’s so easy to get care, and continuation of care, because it’s like one big working network. They are all there, and they all talk with each other,” Kimi says.

Today, Weston is approaching 18 months. Kimi describes him as a “huge cuddle bug.” He recently learned how to blow kisses. “My heart melts when he gives me hugs. He’s always smiling and happy, and he will hug anybody,” she says.

Weston receives regular checkups from his neurologist and dermatologist to watch for any changes. So far, so good. The doctors have helped the military family make care plans for when Nathan finishes his naval postgraduate work and they leave California.

Kimi and Nathan have found comfort and hope in helping to create a community of parents with children who have CMN or NCM. It started with an Instagram page for Weston to keep family, friends, and military friends updated.

“My motivation was to record memories, but all of a sudden people reached out to me, saying their daughter has NCM or they grew up with CMN. I’ve met people from all over the world,” Kimi says.

When she takes Weston out, people comment on the large nevus on his head that grows hair and say it is beautiful and unique. Weston’s older siblings’ friends also comment, saying they “love his big freckle.” It has helped Kimi to see all of Weston, including his nevi, as beautiful.

“He’s different, and different is beautiful,” she says.

Kimi sees purpose in Weston’s condition, as a way to bring people together. She’s passionate about raising awareness about the two conditions. Nathan happily takes on extra responsibilities with Weston to free Kimi up to advocate for better CMN and NCM care and research. Recently, she joined the awareness committee of Nevus Outreach for families with children who have CMN.

“It’s really unique to see parents reaching out to others and creating a community. Usually, having a child with a rare disease is so overwhelming, you are just trying to survive. Kimi is amazing,” Dr. Jeng says.

In 2023, Weston was named a Patient Hero at the Stanford Children’s annual fun run, the Summer Scamper. Nathan pulled together a team called “WildWeston,” inviting his fellow Marines and their families to join in. It was his way of putting his love for his son into action, and Team WildWeston raised over $2,000 for patients of Stanford Children’s.

“The Phelpses are wonderful. They create a positive atmosphere for their children, teaching them that different is normal and beautiful,” Dr. Admani concludes.

https://healthier.stanfordchildrens.org/en/family-turns-newborns-rare-diagnosis-into-something-beautiful/




Lacosamide for neonatal seizures

Moninder Kaur, MVSc, Levon Utidjian, MD MBI, Nicholas S. Abend, MD, MSCE, Kimberley Dickinson, BS, Robert Roebling, MD, Jill McDonald, MA, Mitchell G. Maltenfort, PhD, Nadia Foskett, MD PhD, Sami Elmoufti, Rejean M. Guerriero, DO, Badal G. Jain, MD, Nathan M. Pajor, MD, Suchitra Rao, MD, Renée A. Shellhaas, MD MS, Laurel Slaughter, MD, Christopher B. Forrest, MD PhD. Retrospective Multicenter Cohort Study on Safety and Electroencephalographic Response to Lacosamide for Neonatal Seizures. Pediatric Neurology. DOI:https://doi.org/10.1016/j.pediatrneurol.2024.03.007

Highlights:



Lacosamide was given as second- or third-line therapy in 70% of the 47 neonates.



40% of patients were prescribed lacosamide at discharge to home from the hospital.



19% of patients received lacosamide through the end of the 30-day follow-up period.



No new safety signal was observed with the use of lacosamide in the neonates.



Incidence rate of cardiac arrest per 1000 patient-days was 1.39 (95% CI 0.04-7.74).

ABSTRACT

Background

There is growing evidence supporting the safety and effectiveness of lacosamide in older children. However, minimal data are available for neonates. We aimed to determine the incidence of adverse events associated with lacosamide use and explore the electroencephalographic seizure response to lacosamide in neonates.

Methods

Retrospective cohort study was conducted using data from seven pediatric hospitals from January 2009 to February 2020. For safety outcomes, neonates were followed for ≤30 days from index date. Electroencephalographic response of lacosamide was evaluated based on electroencephalographic reports for ≤3 days.

Results

Among 47 neonates, 98% received the first lacosamide dose in the intensive care units, and 94% had previously received other antiseizure medications before the index date. During the median follow-up of 12 days, 19% of neonates died, and the crude incidence rate per 1000 patient-days (95% confidence interval) of the adverse events by diagnostic categories ranged from 2.8 (0.3, 10.2) for blood or lymphatic system disorders and for nervous system disorders to 10.5 (4.2, 21.6) for cardiac disorders. Electroencephalographic seizures were observed in 31/34 patients with available electroencephalographic data on the index date. There was seizure improvement in 29% of neonates on day 1 and also 29% of neonates on day 2. On day 3, there was no change in 50% of neonates and unknown change in 50% neonates.

Conclusions

The results are reassuring regarding the safety of lacosamide in neonates. Although some neonates had fewer seizures after lacosamide administration, the lack of a comparator arm and reliance on qualitative statements in electroencephalographic reports limit the preliminary efficacy results.

Parsonage-Turner Syndrome in a student athlete

A student athlete in excruciating shoulder pain couldn’t pinpoint why. A Washington University pediatric neurologist at St. Louis Children’s Hospital diagnosed his rare neurological disorder, Parsonage-Turner Syndrome.

Parsonage-Turner Syndrome (PTS) is a neurological disorder characterized by sudden onset of severe pain in the shoulder or arm followed by weakness in the affected area. It is rare — thought to occur in about 1 to 3 people out of 100,000 each year — and especially uncommon in children. When a pediatric patient was referred to the  Children’s Specialty Care Center-West County in St. Louis, Missouri, with pain in his left shoulder, providers initially thought it was a rotator cuff injury, but imaging did not show anything out of the ordinary. After the same patient presented with extreme weakness in the same arm, a Washington University pediatric neurologist was able to diagnose the child with PTS by using a nerve conduction study and electromyogram to identify nerve inflammation in multiple areas of the brachial plexus. The neurologist was able to quickly refer the patient to physical therapy at the Washington University and St. Louis Children’s Young Athlete Center, which aided in his nearly full recovery. 

When an elementary-aged patient was referred to the Children’s Specialty Care Center-West County in St. Louis, Missouri, with onset of left shoulder pain, providers initially suspected that he had torn his rotator cuff. The patient was an active child, a competitive hockey player — but the family couldn’t pinpoint what might have caused an injury or pain. An X-ray revealed nothing out of the ordinary. An MRI was also normal. But the pain became unbearable. 

When, a month later, the same patient was experiencing severe weakness in his left shoulder, tests confirmed it was something more rare: severe denervation of the suprascapular and axillary nerves in the left shoulder, suggestive of severe neuropathy of both nerves and consistent with an uncommon neurological condition called Parsonage-Turner Syndrome (PTS) — almost unheard of in pediatric patients.

PTS, also referred to as idiopathic brachial plexopathy or neuralgic amyotrophy, is estimated to occur in 1 to 3 people out of every 100,000 individuals each year, but because it is often not diagnosed or misdiagnosed, the incidence is difficult to determine. 

The condition presents with:

Abrupt onset of shoulder pain, usually unilaterally

Progressive motor weakness

Dysesthesia

Numbness

The cause of PTS is not well understood, but it has been observed in the following scenarios:

Postoperatively

Post infection

Post traumatic event

Postvaccination

Although information on PTS in pediatrics is scarce and the condition is difficult to diagnose in its acute stage, recovery can be favorable, additional testing limited and surgical exploration avoided if the diagnosis is made early. Doing so, however, requires a combination of expertise as well as care that straddles neurology, orthopedics, and physical therapy. 

Three things tipped off Sheel Pathak, MD, a Washington University pediatric neurologist at St. Louis Children’s Hospital, that the patient might be experiencing a neurological problem with his brachial plexus rather than just an orthopedic issue. The first two were the profound weakness and asymmetry of his scapula. The third was a detail from the patient’s history: He hadn’t experienced a hockey injury, but he had reported pulling a heavy object — a large bag — out of a car, stretching his shoulder and neck, before the pain's onset.

Pathak suspected that the patient was experiencing nerve damage and ordered both a nerve conduction study and an electromyogram. The results of the testing showed nerve inflammation in multiple areas of the brachial plexus. Knowing the patient’s story, Pathak pointed to PTS as the cause. 

“Trauma is one of the causes of that, and he had yanked on that bag and hurt himself, so we thought that was the mechanism,” he says. “He had a story that made sense and electrodiagnostic studies that supported an inflammatory process to the brachial plexus.”

Pathak knew the next step in treatment was physical therapy and referred the patient to the Washington University and St. Louis Children’s Young Athlete Center, conveniently located within the Children’s Specialty Care Center.

When the patient began physical therapy for PTS at the Young Athlete Center, he was only able to actively raise his left arm to 70 degrees of shoulder flexion and 40 degrees of shoulder abduction; normal ranges are 180 degrees for both motions. The patient only had trace contraction of all rotator cuff muscles and was severely limited in his ability to perform any overhead activity.

Although PTS is rare in pediatric patients, Gabrielle Griffin, PT, DPT, the physical therapist at the Young Athlete Center who treated the patient, was able to find a case study similar to the patient’s case that outlined neuromuscular electric stimulation (NMES) protocol to activate and strengthen the patient’s muscle. She paired the protocol with progressive rotator cuff strengthening and saw the patient for seven months, first twice a week before moving to once a week. 

When the patient started physical therapy, he had barely any activation of the rotator cuff muscles and had trace muscle function in some areas. Attempting to move through a full range of motion, then, was not an option if he could not activate his muscles in a gravity-lessened position. Instead, Griffin focused on early strengthening isometrics, such as pressing and holding a shoulder into a wall, working on activating muscle fibers. From there, therapy was a gradual progression of moving those muscles against gravity and adding resistance. 

One challenging aspect of the patient’s care was that there was no indication of how long the weakness would last. During therapy, the patient was unable to play hockey or even sports at school during recess. Unsure of how long his symptoms would last, if he would make a full recovery or if he would play sports again, he struggled emotionally with his condition. 

“His mom did pull me aside and tell me that she was noticing some signs of depression because he couldn’t play hockey,” Griffin says.

Griffin addressed the patient’s morale by implementing positive psychological coaching strategies to motivate the patient. Each week, she would point out progress, be it gaining even 2 to 3 degrees of motion. 

“In our sessions, we kept it as fun as possible,” Griffin says. “He got to pick out music to play and however I could incorporate hockey into the sessions, we did that.” The Young Athlete Center had space to accommodate a hockey goal, and the patient was able to practice taking shots, a taste of his former activity that spurred him on. On his last day of therapy, he had a nearly full range of motion and very close to manual muscle testing strength in all planes. The patient not only returned to playing competitive hockey, but he also moved up to a more advanced team.

A year after the patient entered care within St. Louis Children’s Hospital, the Washington University neurology team found he only had mild weakness of shoulder rotation on his left side, an excellent outcome thanks in part to a speedy diagnosis and access to high-quality physical therapy. “Identifying a good pattern of this, being able to say, ‘Yes, this is Parsonage-Turner Syndrome’ based on what we see on the electrodiagnostic studies helps prevent some diagnostic odyssey, more tests and unnecessary treatments,” Pathak says. “We were able to identify it and treat him so he could get back to doing what he loves.”

https://www.doximity.com/doc_news/v2/sponsored_entries/aHR0cHM6Ly9jYW1wYWlnbnMuZG94aW1pdHkuY29tL2FwaS92Mi9kZWxpdmVyaWVzLzg4M2Q5M2EyLTVhNDAtNDQ2NS1hOTA2LWRiMTQyYzU1Y2QyZj9jaGFubmVsPW5ld3NmZWVk?channel=newsfeed

See: https://issuu.com/st.louischildrenshospital/docs/slch_foundationmagazine_fall2022_web

https://www.stlouischildrens.org/health-resources/pulse/solving-medical-mystery-takes-teamwork


Monday, April 1, 2024

Diffuse intrinsic pontine glioma 4

Aubrey Rothery, 7, was diagnosed with an inoperable brain tumor after his parents noticed he was having trouble with coordination and balance

A 7-year-old from the UK has been diagnosed with a rare form of an inoperable brain tumor — and its initial symptoms caused him to bump into things and lose his balance.

'It was very subtle to start with, he was bumping into bits of furniture,' Aubrey Rothery’s father, Andrew told SWNS, via The Daily Mail.

'He’d grown a lot and is quite gangly and lively and active and we thought he’s just not noticing where he’s going,” he told the outlet.

However, Aubrey’s loss of balance continued, even causing him to be sent home from school. His pediatrician advised the family to take him to the hospital — where he was diagnosed with a Diffuse Intrinsic Pontine Glioma (DIPG).


It’s an aggressive, rare tumor that develops in the brainstem, and largely affects children, the National Library of Medicine says, adding that the prognosis for those with the tumor is grim.

“Most patients survive less than one year.”

IThe tumor may be linked to brain development, the National Library of Medicine says.

“Studies suggest that the disease process is created by particular cells that exist in very high concentrations, while the cerebral tissue is developing. This theory is supported by the fact that this tumor rarely occurs in adults and almost always occurs in mid-childhood (ages 5 to 10), a period in which the cerebral tissue is very active in development.”

His family was shocked to learn the news.

'It feels like in some ways like hope is the most important thing we have to hold on to — the diagnosis is harsh, and the prognosis is pretty bleak,” his father said, via The Daily Mail. 'We were just in pieces, it was an incredible shock.'”

“This can’t be happening to our beloved beautiful boy,” he told the outlet.

Treatment includes steroids and radiation treatment, which a GoFundMe set up for the family says Aubrey is currently undergoing.

“We hope [it] will slow or stop the growth of the tumour for between 6 - 18 months. This will give us time to find a treatment that can help over the longer term,” the GoFundMe says.

The family shared that they’re looking into alternate treatments, like drug trials, natural medication, and craniosacral therapy, which the Mayo Clinic says is a massage technique that aims to offer pain relief from cancer treatment.

“Aubrey’s Wish is simple – he just wants to get back to how life was before the 23rd of February,” when he was diagnosed, the GoFundMe says.

“He wants to be well, he wants to be able to walk un-aided, he wants to kick a football around and go to the playground with his brothers and sisters.”

https://people.com/7-year-old-brain-tumor-bump-into-things-aubrey-rothery-8621598